Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
May 5th, 2022
2.4K views
This protocol describes the process of the generation and characterization of mouse urothelial organoids harboring deletions in genes of interest. The methods include harvesting mouse urothelial cells, ex vivo transduction with adenovirus driving Cre expression with a CMV promoter, and in vitro as well as in vivo characterization.
Overview
This protocol describes a rapid and efficient method for generating bladder cancer organoids from mouse urothelial cells through ex vivo gene editing. The approach allows for quick characterization of organoids with specific gene deletions.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Oncology
Background
- Bladder cancer organoids can be generated from normal mouse urothelial cells.
- Traditional methods involve extensive mouse breeding, which is time-consuming.
- Ex vivo gene editing provides a faster alternative.
- Adenovirus transduction is utilized for efficient gene deletion.
Purpose of Study
- To develop a protocol for generating bladder cancer organoids.
- To facilitate the study of gene function in bladder cancer.
- To reduce the time required for organoid generation.
Methods Used
- Harvesting mouse urothelial cells.
- Ex vivo transduction with adenovirus driving Cre expression.
- Characterization of organoids in vitro and in vivo.
- Use of sterile instruments and reagents for dissection and culture.
Main Results
- Successful generation of bladder cancer organoids from edited cells.
- Efficient adenovirus transduction leading to gene deletions.
- Characterization of organoids confirmed their viability and relevance.
- Reduction in workflow time compared to traditional breeding methods.
Conclusions
- The protocol provides a quick and efficient method for organoid generation.
- Ex vivo gene editing is a valuable tool for cancer research.
- This approach can accelerate the study of bladder cancer biology.
Frequently Asked Questions
What are bladder cancer organoids?
Bladder cancer organoids are 3D cell cultures derived from bladder tissue that mimic the tumor environment.
How does ex vivo gene editing work?
Ex vivo gene editing involves modifying cells outside the organism before reintroducing them, allowing for targeted genetic changes.
What is the role of adenovirus in this protocol?
Adenovirus is used to deliver Cre recombinase to the urothelial cells, facilitating gene deletion.
Why is this method preferred over traditional breeding?
This method is faster, taking weeks instead of years, and allows for immediate analysis of genetic modifications.
What are the implications of this research?
This research can enhance our understanding of bladder cancer and potentially lead to new therapeutic strategies.
Executive Industry Relevance
Rapid ex vivo organoid generation using adenovirus-Cre mediated gene deletions in mouse urothelial cells enables accelerated interrogation of tumor suppressor function in bladder cancer models. This approach bypasses lengthy breeding cycles, providing a scalable and reproducible platform for functional target validation and mechanistic de-risking at the discovery stage. The system supports efficient portfolio triage by enabling direct assessment of genetic alterations in disease-relevant organoid models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rapid functional validation of tumor suppressor genes in a controlled ex vivo system.
- Supports mechanistic de-risking by isolating the effects of specific gene deletions in urothelial cells.
- Facilitates predictive confidence in target selection by modeling genetic drivers in organoid cultures.
Screening & Assay Development
- Provides standardized, genetically defined organoid systems for downstream compound screening.
- Delivers reproducible and scalable organoid cultures suitable for quantitative phenotypic assays.
- Enables robust assay development by confirming gene deletion via PCR and marker expression by immunofluorescence.
Translational & Preclinical Research
- Aligns organoid phenotypes with in vivo tumor characteristics for translational continuity.
- Supports preclinical modeling by enabling xenograft expansion and serial passage of engineered organoids.
- Allows for biomarker validation through immunohistochemistry of lineage and subtype markers.
Pipeline & Workflow Integration
This ex vivo organoid workflow bridges early discovery and preclinical research by enabling rapid hypothesis testing and functional genomics in disease-relevant systems.
- Discovery Biology: Accelerates hypothesis-driven gene function studies and pathway clarification in bladder cancer.
- Screening: Establishes assay-ready organoids with confirmed genetic status for compound evaluation.
- Analytics: Provides quantitative PCR and immunostaining outputs for rigorous condition comparison.
- Translational Research: Maintains phenotypic fidelity from organoid to xenograft for preclinical alignment.
- Enterprise Reuse: Offers a modular, reusable platform for diverse genetic and pharmacological studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Delivers standardized, reproducible, and scalable organoid production workflows.
- Strategic Value: Enables faster go/no-go decisions and improves capital efficiency by shortening model development timelines.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of genetically validated targets.
Implementation Considerations
- Requires expertise in organoid culture, gene editing, and molecular characterization.
- Demands access to sterile tissue processing, adenoviral vectors, and analytical platforms for PCR and immunostaining.
- Necessitates cross-team standardization of dissociation and transduction protocols for reproducibility.
- Adaptable to different genetic backgrounds and cell types with appropriate adenoviral constructs.
- Limited by dissociation time and cell-type specificity, which may affect organoid composition and purity.
Biopharma FAQs
Why does null hypothesis testing matter for adenovirus-Cre gene deletion studies?
Null hypothesis testing ensures that observed phenotypic changes in organoids are attributable to specific gene deletions rather than background variation, supporting robust target validation and mechanistic clarity in early discovery.
How does independent variable isolation fit the ex vivo organoid workflow?
By using floxed alleles and adenovirus-Cre transduction, the protocol isolates the effect of targeted gene deletions, enabling precise assessment of each genetic alteration's impact within the organoid system.
What do quantitative PCR and immunostaining measurements enable in this protocol?
Quantitative PCR confirms gene deletion efficiency, while immunostaining validates lineage marker expression, together providing rigorous, reproducible readouts for comparing experimental conditions and supporting downstream screening.
Why are replication requirements critical for cross-functional organoid studies?
Replication ensures that organoid generation, gene deletion, and phenotypic outputs are consistent across experiments and teams, enabling reliable data integration and collaborative decision-making in R&D pipelines.
Which statistical analysis capabilities are required before implementing organoid-based gene deletion assays?
Robust statistical analysis of PCR, immunostaining, and phenotypic data is essential to validate gene deletion efficiency, assess reproducibility, and support confident advancement decisions in discovery and preclinical workflows.
Chapters in this video
0:04
Introduction
0:45
Dissection of Mouse Bladder
2:09
Dissociation of Urothelial Cells
4:41
Counting and Resuspending Cells
5:27
Adenoviral Transduction and Plating Organoids
7:06
Results: Characterization of Triple Knockout Organoids via Ex Vivo Adenovirus-Cre Recombinase
8:31
Conclusion
